ADVA
1.4.2020 09:02:08 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that the European Advanced Networking Test Center (EANTC) has validated the interoperability of its unique carrier-grade network operating system (NOS) with routers and network management systems from a wide range of vendors. ADVA’s Ensemble Activator successfully demonstrated interoperability in a series of tests showing how disaggregated packet devices can significantly enhance the scale and functionality of networks. The software-based NOS, which turns bare-metal switches into powerful packet network devices, proved fully compatible with third-party switching and routing devices while supporting segment routing and MPLS Layer 3 services. What’s more, it showed ease of integration into third-party management systems through open interfaces for telemetry streaming and SDN control. Conducted at the EANTC’s facility in Berlin, the tests highlight the value of openness and show how Ensemble Activator can complement legacy packet networks with disaggregated packet devices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200401005039/en/
“Putting our Ensemble Activator through EANTC’s rigorous tests emphasizes the commitment to openness and interoperability that underpins all ADVA innovation. But we’re also showing the industry how we can bring something special to Layer 3. Our years of experience with lower layer solutions give us a unique understanding of the operational aspects of networks,” said Eli Angel, VP, product line management, ADVA. “Our Ensemble Activator is proven to enable high-value disaggregated cell site gateway solutions, bringing the agility of software-based feature development to mobile networks. Now, we’re going even further and extending our unique MEF 3.0-certified solution with higher layer networking capabilities. These tests highlight how our Ensemble Activator supports segment routing and MPLS. What more, our disaggregated packet solution releases communication service providers from vendor lock-in and delivers total agility.”
Engineered specifically for white box switching, ADVA’s Ensemble Activator is the result of years of experience in deploying optical, Carrier Ethernet and IP/MPLS networks. The NOS is designed for zero-touch provisioning using the Open Networking Install Environment (ONIE) framework. Its success in the latest round of EANTC tests demonstrates how Ensemble Activator’s open management and control interfaces support easy integration into multi-vendor networks. ADVA’s strategy of extending its software capabilities from Layer 2 to higher layer functions offers the market a fresh approach to deploying flexible, feature-rich software-based MPLS routing and segment routing solutions in an open environment. ADVA’s long experience of building disaggregated telecommunication infrastructure will bring a host of benefits to operators and users of virtual private networks.
“Our evaluation confirms that Ensemble Activator successfully interworked with third-party routers and network management systems. In environments featuring technology from other major vendors, ADVA’s disaggregated software NOS was verified in tests focused on Layer 2 and Layer 3 VPNs, segment routing, and control and data plane capabilities,” commented Carsten Rossenhövel, managing director, EANTC. “This latest interoperability event was a major success with more than 100 attendees from 16 vendors, including many participating remotely. Its program reflected a shift across the industry to software-defined networking with many testing scenarios involving programmability and manageability. ADVA’s Ensemble Activator easily integrated and successfully interoperated in several of these tests, such as those focused on vendor-neutral Layer 3 segment routing and telemetry streaming.”
Further information on the interoperability testing is available on the EANTC website: https://adva.li/eantc-2020 .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About EANTC
EANTC (European Advanced Networking Test Center) is internationally recognized as one of the world's leading independent test centers for telecommunication technologies. Based in Berlin, Germany, the company offers vendor-neutral consultancy and realistic, reproducible high-quality testing services since 1991. Customers include leading network equipment manufacturers, tier-1 service providers, large enterprises and governments worldwide. EANTC's proof of concept, acceptance tests and network audits cover established and next-generation fixed and mobile network technologies. www.eantc.de
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200401005039/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
